6-acetoxy-1-naphthoic acid | 149066-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-acetoxy-1-naphthoic acid
• 英文别名: 6-acetoxy-[1]naphthoic acid；6-Acetoxy-[1]naphthoesaeure；6-acetyloxynaphthalene-1-carboxylic acid
• CAS: 149066-23-9
• 化学式: C₁₃H₁₀O₄
• 分子量: 230.22
• InChiKey: VTNGPRTXAFPVTG-UHFFFAOYSA-N

物化性质

• 沸点：
  438.4±18.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-acetoxy-1-naphthoic acid 生成
  参考文献：
  名称：

  Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof

  摘要：

  本发明涉及一种制备化合物6-(7-4(1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-氧基)-N-甲基-1-萘酰胺（I）及其药学上可接受的盐的高产率和纯度的方法。该方法相较于先前描述的方法具有各种优点，特别是避免了酰基叠氮中间体及其Curtius重排的使用。还描述了用于制备化合物（I）的新型中间体。

  公开号：

  US08642767B2
• 作为产物：
  描述：

  6-甲氧基萘甲酸 在 吡啶 、 氢溴酸 、 溶剂黄146 作用下， 生成 6-acetoxy-1-naphthoic acid
  参考文献：
  名称：

  脱氧皮质酮的一些萘类似物。

  摘要：

  DOI：

  10.1021/ja01202a006

文献信息

• Spiro Substituted Compounds As Angiogenesis Inhibitors
  申请人：Chen Guoqing Paul

  公开号：US20080227812A1

  公开（公告）日：2008-09-18

  The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.

  本发明涉及Formula I的螺环（四碳）取代化合物，以及其制备方法、含有其作为活性成分的药物组合物、用于治疗与血管生成相关的疾病状态的方法，如与蛋白酪氨酸激酶相关的癌症，以及它们作为药物在生产中用于减少温血动物（如人类）中酪氨酸激酶抑制效果的用途。
• Spiro substituted compounds as angiogenesis inhibitors
  申请人：Advenchen Laboratories, LLC

  公开号：US08163923B2

  公开（公告）日：2012-04-24

  The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.

  本发明涉及公式I的螺环（四碳）取代化合物，其制备方法，含有它们作为活性成分的制药组合物，用于治疗与血管生成有关的疾病状态的方法，例如与蛋白酪氨酸激酶相关的癌症，以及它们作为药物用于在温血动物，如人类中产生抑制酪氨酸激酶减少效果的制剂。
• SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS
  申请人：CHEN Guoqing Paul

  公开号：US20120165371A1

  公开（公告）日：2012-06-28

  The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.

  本发明涉及一种式子I的螺环（四羰基）取代化合物，其制备方法，含有其作为活性成分的制药组合物，用于治疗与血管生成相关的疾病状态的方法，例如与蛋白酪氨酸激酶相关的癌症，以及它们作为药物用于在温血动物（如人类）中产生抑制酪氨酸激酶的减少效果。
• Thermotropic liquid-crystalline aromatic copolymers
  申请人：ENICHEM S.p.A.

  公开号：EP0375036A1

  公开（公告）日：1990-06-27

  Liquid-crystalline, completely aromatic copolyesters are disclosed, which are endowed with a heat stability not lower than 350° C, and are constituted by a succession of repeatitive units containing: wherein A and B, which can be either equal to, or different, from, each other, can be either -O- or -CO- and one of the following moieties: in which Ar can be 1,4-phenylene, 2-monosubstituted-1,4-­phenylene or 4,4′-diphenylene. Also copolyesters also containing amidic bonding groups are disclosed.

  本发明公开了液晶型完全芳香族共聚聚酯，其热稳定性不低于 350°C，由连续的重复单元构成，这些重复单元包含： 其中，A 和 B 可以相互等同或不同，可以是 -O- 或 -CO- 以及下列分子之一： 其中 Ar 可以是 1,4-亚苯基、2-单取代-1,4-亚苯基或 4,4′-二亚苯基。 此外，还公开了同样含有酰胺键基团的共聚多酯。
• Liquid crystal polymer composition
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0565353A1

  公开（公告）日：1993-10-13

  A liquid crystal polymer composition comprises (A) 100 parts by weight of a liquid crystal polyester and/or liquid crystal polyesteramide capable of forming an anisotropic melt and (B) a liquid crystal polymer composition containing 5 to 300 parts by weight of a potassium titanate whisker having a pH of 6 to 8, wherein, the melt viscosity of the composition is 12 to 300 Pa·sec, and the weight average fiber length of the potassium titanate whisker in the composition is at least 4.5 µm.

  一种液晶聚合物组合物包括：(A) 100 份（按重量计）能形成各向异性熔体的液晶聚酯和/或液晶聚酯酰胺；(B) 含有 5 至 300 份（按重量计）pH 值为 6 至 8 的钛酸钾晶须的液晶聚合物组合物，其中，组合物的熔体粘度为 12 至 300 帕-秒，组合物中钛酸钾晶须的重量平均纤维长度至少为 4.5 微米。